Welcome to our dedicated page for Wellgistics Health SEC filings (Ticker: WGRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Wellgistics Health, Inc. (NASDAQ: WGRX) SEC filings page on Stock Titan brings together the company’s official disclosures to U.S. regulators, including current reports on Form 8-K, quarterly reports on Form 10-Q, and related exhibits. These documents provide detail on Wellgistics Health’s operations as a pharmacy physical and technology enabling health IT company that connects more than 6,500 pharmacies and over 200 manufacturers through wholesale distribution, digital prescription routing, direct-to-patient delivery, and AI-powered hub services.
Through its filings, Wellgistics has reported material events such as the license agreement with DataVault AI Inc. for intellectual property used to develop its PharmacyChain™ manufacturer-to-patient blockchain-enabled smart contracts platform, sponsorship and licensing arrangements related to Dream Bowl 2026, and debt conversion agreements. Filings also describe the launch and positioning of the EinsteinRx™ pharmacy dispensing optimization AI platform, changes in independent registered public accounting firms, and the reporting of quarterly financial results.
Investors can also review an 8-K describing a Nasdaq notice regarding the company’s minimum bid price deficiency and the associated compliance period, which outlines potential implications for the continued listing of WGRX on The Nasdaq Capital Market. These regulatory documents offer insight into governance, capital structure, strategic partnerships, and risk factors referenced in the company’s public communications.
On Stock Titan, SEC filings for WGRX are supplemented with AI-powered summaries that highlight key terms, financial metrics, and business developments from lengthy documents. Users can quickly identify items related to licensing arrangements, sponsorship agreements, auditor changes, and listing compliance, while still having access to the full text as filed with the SEC. The page also provides convenient access to forms associated with insider and shareholder-related activity when available, helping users track how Wellgistics Health’s regulatory profile evolves over time.
Wellgistics Health, Inc. filed a Form 8-K under Item 7.01 (Regulation FD) to furnish a press release dated October 13, 2025 as Exhibit 99.1.
The company states the furnished information is not deemed “filed” for purposes of Section 18 of the Exchange Act and is not incorporated by reference. The press release contains forward-looking statements, and readers are directed to risk disclosures in the company’s SEC filings, including its Form S-1 declared effective on September 25, 2025.
Wellgistics Health, Inc. (WGRX) reported an initial insider ownership filing. A director filed a Form 3 with an event date of 10/02/2025, indicating no securities are beneficially owned.
The filing was made by one reporting person, and a Power of Attorney was included as Exhibit 24.1.
Wellgistics Health, Inc. reported that three senior executives resigned on October 6, 2025. Chief Executive Officer Brian Norton and Chief Financial Officer Mark DiSiena each resigned effective 5:00 p.m. EST, and Chief Operating Officer Tony Madsen resigned effective 8:00 p.m. EST the same day.
On October 7, 2025, the board appointed Eric Sherb as interim Chief Financial Officer. Sherb, age 38, is a CPA with 16 years of experience in accounting advisory, auditing, mergers and acquisitions, and capital markets transactions including IPOs and SPAC deals.
The company had previously entered into a consulting agreement on September 8, 2025 with EMS Consulting Services, Inc., an entity controlled by Sherb, which was amended to cover his interim CFO role. Under this agreement, he provides CFO-level services at hourly rates of $185 for CPA services and $80 for bookkeeping or controller-related work, and the agreement may be terminated by either party at any time.
Wellgistics Health, Inc. reported the immediate removal of two directors from its board. The filing states that Rebecca Shanahan and Michael Peterson were removed as directors effective immediately. At the time of their removals, Ms. Shanahan served on the Ethics Committee and Mr. Peterson served as the chair of the Audit Committee. The notice appears as a concise disclosure of governance changes without additional explanation of reasons, replacements, or related corporate actions.
Wellgistics Health, Inc. (WGRX) is offering 7,142,862 shares of Common Stock at $0.70 per share, producing approximately $4,650,003 of proceeds before expenses with placement agent fees of $350,000. After the offering and assuming no warrants are exercised, the company expects 91,406,962 shares outstanding. The filing discloses a consolidated net loss of $39,103,367 for a reported period, with weighted average common shares of 56,863,720 and a net loss per share of $0.63 in one table. Pro forma and segment tables show other reported net losses (for example, $10,592,215 and $6,856,226 in separate schedules). The company reports an actual net tangible book value per share before the offering of $(0.47) and an offering price of $0.70, but the filing leaves some post-offering per-share calculations blank. The company completed the Wellgistics acquisition with cash consideration terms including a $10 million closing payment and issuance of a $17,500,000 note payable (amended terms), plus issuance of 3,999,335 restricted shares valued at $15,000,000 as equity consideration. A U.S. utility patent application titled "Method and Apparatus for Prescription Management" was filed July 26, 2022 and submitted September 26, 2023 to protect the company’s tech and hub platform.
Wellgistics Health, Inc. is amending its S-1 registration to offer up to 5,357,142 shares of Common Stock at an assumed public offering price of $1.40 per share. After the offering (and assuming full exercise of any Pre-Funded Warrants and no exercise of accompanying Warrants) the company would have 89,621,242 shares outstanding. The filing discloses a recent acquisition (Wellgistics) with pro forma recognition of substantial goodwill and intangible assets and transaction consideration that included a cash component and issuance of 3,999,335 restricted shares valued at $15,000,000.
The company reported consolidated losses in the periods presented, including a combined net loss of $39,103,367 (weighted average shares 56,863,720, net loss per share $0.69) and other historical net losses (for a prior period of $10,592,215). The pro forma balance sheet includes a note payable originally $15,000,000 that was amended to a principal of $17,500,000 payable in installments. The filing also discloses a U.S. utility patent application titled "Method and Apparatus for Prescription Management."
Wellgistics Health, Inc. (WGRX) files an amended S-1 registration describing its proposed public offering, recent acquisition accounting, capital structure and historical results. The company discloses a consolidated net loss of $39,103,367 and a weighted average of 56,863,720 common shares, implying a reported net loss per share of $0.63 in the presented period. The pro forma capital table reflects the issuance and sale of 11,182,565 shares subsequent to June 30, 2025 and potential additional shares or pre-funded warrants in the offering.
The filing explains material transaction terms: a patent application titled “Method and Apparatus for Prescription Management” (filed July 26, 2022; submitted Sep 26, 2023), issuance of 3,999,335 restricted shares valued at $15,000,000 as acquisition consideration, and a note payable originally $15,000,000 that was amended to a principal of $17,500,000 with scheduled installments in 2026 and 2028. The company reports a net tangible book value per share before the offering of $(0.60) and names Colonial Stock Transfer Company as transfer agent. Major insider holdings disclosed include Brian Norton (10,990,247 shares; 13.04%) and Suren Ajjarapu (10,445,447 shares; 12.40%).
Wellgistics Health, Inc. filed a current report to share investor communications it is using at upcoming events. On September 5, 2025, the company issued a press release announcing that it will present at three business conferences during September 2025, and that release is furnished as Exhibit 99.1.
The company is also providing an updated corporate presentation and a fact sheet, furnished as Exhibits 99.2 and 99.3, which it plans to use at these conferences and in future meetings with prospective investors and strategic partners. These materials, dated September 8, 2025, have been posted to the company’s investor website.
The press release, presentation, and fact sheet are furnished rather than filed, so they are not subject to certain Exchange Act liabilities and are not automatically incorporated into other securities law filings. The company emphasizes that these materials contain forward-looking statements and refers readers to its Form 10‑K and subsequent Form 10‑Q filings for a detailed discussion of related risks.
Wellgistics Health, Inc. entered into a Business Loan and Security Agreement with Agile Capital Funding, LLC for a principal amount of
Separately, the company issued a press release on August 27, 2025 announcing the introduction of a fully customizable artificial intelligence engine integrated into its tech and hub platform. This press release is furnished as an exhibit and includes forward-looking statements subject to risks described in the company’s SEC reports.
Wellgistics Health, Inc. files an amended S-1 showing a combined set of operations and pro forma adjustments tied to the acquisition of Wellgistics. The company reported a consolidated net loss of $39,103,367 in one presented period with a weighted average of 56,863,720 shares and reported net loss per share figures of $0.63 and $0.69 in related tables. The filing discloses an offering of common stock (shares unspecified in this excerpt) at an assumed public price tied to the Nasdaq closing price on a 2025 date and shows outstanding common shares of 72,881,535 issued and 63,144,817 outstanding as of June 30, 2025.
The company details material transaction terms from the Wellgistics acquisition including a $15,000,000 note payable due in three equal annual installments beginning February 14, 2026, and issuance of 3,999,335 restricted shares recognized at a fair value of $15,000,000 as equity consideration. A U.S. utility patent application titled “Method and Apparatus for Prescription Management” was filed (July 26, 2022; submitted Sept 26, 2023) covering the tech and hub platform. Financial tables show material operating losses, high general and administrative expenses, and pro forma adjustments to goodwill and intangible assets.